Sustained drug-free remission in giant cell arteritis
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Sustained drug-free remission (SDFR) is achieved by about a quarter of patients with giant cell arteritis (GCA) within 3-4 years. Relapses and initial IV methylprednisolone use predict longer glucocorticoid needs.
Area Of Science
- Rheumatology
- Immunology
- Internal Medicine
Background
- Giant cell arteritis (GCA) is a systemic vasculitis affecting large arteries.
- Long-term glucocorticoid therapy is standard but associated with significant side effects.
- Identifying predictors of sustained drug-free remission (SDFR) is crucial for optimizing GCA management.
Purpose Of The Study
- To determine the frequency and timing of SDFR in GCA patients.
- To identify factors that predict the achievement of SDFR.
- To assess the risk of recurrence after achieving SDFR.
Main Methods
- Retrospective review of 872 GCA patients from the Spanish multicentre registry (ARTESER).
- Minimum follow-up of 2 years.
- SDFR defined as ≥12 months without GCA activity after treatment cessation.
Main Results
- SDFR was achieved in 21.2% of patients within 4 years.
- Cumulative SDFR rates were 6.3% (2 years), 20.5% (3 years), and 25.3% (4 years).
- Relapses and need for IV methylprednisolone at diagnosis predicted lower likelihood of SDFR.
- Recurrence was low (2.7%) with a median onset of 19 months post-SDFR.
Conclusions
- Approximately one-quarter of GCA patients achieve SDFR within 3-4 years.
- SDFR is associated with faster prednisone reduction and fewer relapses.
- Relapses and initial IV methylprednisolone boluses are predictors of long-term glucocorticoid dependence.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...